Scarica l'app Stockscreener
7.1998
1.62%
-0.1402
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Precedente Chiudi:
$7.34
Aprire:
$7.38
Volume 24 ore:
42.99M
Relative Volume:
2.02
Capitalizzazione di mercato:
$7.12B
Reddito:
$1.31M
Utile/perdita netta:
$-597.65M
Rapporto P/E:
-7.4225
EPS:
-0.97
Flusso di cassa netto:
$-425.62M
1 W Prestazione:
+30.82%
1M Prestazione:
+243.87%
6M Prestazione:
+141.51%
1 anno Prestazione:
+131.45%
Intervallo 1D:
$7.05
$7.8755
Intervallo di 1 settimana:
$5.71
$8.28
Portata 52W:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Nome
Immunitybio Inc
Settore
Industria
Telefono
(844) 696-5235
Indirizzo
3530 JOHN HOPKINS COURT, SAN DIEGO
Confronta IBRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
7.225 | 7.23B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.95 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
749.78 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
811.57 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
360.78 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
339.19 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-20 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | Iniziato | H.C. Wainwright | Buy |
| 2025-01-10 | Iniziato | BTIG Research | Buy |
| 2023-05-12 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | Iniziato | Jefferies | Buy |
Immunitybio Inc Borsa (IBRX) Ultime notizie
IBRX Stock Sees Volatile Session – ImmunityBio’s Update In Phase 2 Glioblastoma Trial Sparks Buzz - Asianet Newsable
ImmunityBio Shares Surge on Regulatory Progress and Short Squeeze Dynamics - AD HOC NEWS
ImmunityBio Says Median Overall Survival Not Yet Reached in Phase 2 Glioblastoma Trial - 富途资讯
BTIG Maintains ImmunityBio(IBRX.US) With Buy Rating, Raises Target Price to $9 - 富途资讯
ImmunityBio reports survival gains in glioblastoma trial - grafa.com
ImmunityBio Reports New Progress in GBM Treatment with 19 Patients Alive - Intellectia AI
ImmunityBio Reports Median Overall Survival Not Yet Reached and Lymphopenia Reversed in Recurrent Glioblastoma Patients Receiving ANKTIVA® Plus CAR-NK, Chemo-Free Therapy - galvnews.com
Bladder Cancer Vaccines Market Poised for Rapid Growth at 21.32% - openPR.com
A Look At ImmunityBio (IBRX) Valuation After FDA Anktiva Pathway And Saudi Approvals - simplywall.st
ImmunityBio’s Stock Surges Amidst Impressive Clinical Trial Results and Strategic Approvals - timothysykes.com
ImmunityBio (NASDAQ:IBRX) Hits New 52-Week HighHere's What Happened - MarketBeat
Immunitybio stock price target raised to $9 from $6 at BTIG on improved outlook By Investing.com - Investing.com South Africa
Immunitybio stock price target raised to $9 from $6 at BTIG on improved outlook - Investing.com
Biotech Stocks To Keep An Eye OnJanuary 22nd - MarketBeat
ImmunityBio (IBRX) stock rises before the bell after FDA talks point to new ANKTIVA filing - TechStock²
Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That” - Insider Monkey
ImmunityBio Shares Surge on Regulatory and Commercial Milestones - AD HOC NEWS
ImmunityBio shares jump after constructive FDA talks on bladder cancer therapy - MSN
NK Cell Therapy Market 2034: 7MM Outlook, 30+ Active Developers, IND/NDA Momentum, and Next-Gen CAR-NK Innovations Driving Immunotherapy Advances | DelveInsight - Barchart.com
Director Barry Simon Sells 151,967 Shares of ImmunityBio Inc (IB - GuruFocus
Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells 25,000 Shares of Stock - MarketBeat
ImmunityBio (NASDAQ:IBRX) Director Barry Simon Sells 151,967 Shares - MarketBeat
Insider Selling: ImmunityBio (NASDAQ:IBRX) Director Sells 50,000 Shares of Stock - MarketBeat
Why Is ImmunityBio Stock Back In Retail Spotlight Today? - Stocktwits
Stock Market Today, Jan. 21: ImmunityBio Rises Again As Short-Sellers Face Losses - Yahoo Finance
ImmunityBio Faces a Booming Stock Surge With Remarkable Clinical Progress - StocksToTrade
ImmunityBio rally causes $492M paper losses for short sellers - MSN
ImmunityBio (NASDAQ:IBRX) Shares Gap DownShould You Sell? - MarketBeat
ImmunityBio stock price dips today as IBRX cools off after FDA resubmission update - TechStock²
Promising Biotech Stocks To ConsiderJanuary 21st - MarketBeat
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
Billionaire Soon-Shiong’s Biotech Stock Burns Shorts With Surge - Bloomberg
ImmunityBio Shares Surge on Streamlined FDA Pathway for Cancer Drug - AD HOC NEWS
ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer - TechStock²
ImmunityBio (IBRX) Rockets on 12th Day, Hits Fresh High - Finviz
HC Wainwright Weighs in on ImmunityBio FY2030 Earnings - MarketBeat
ImmunityBio rises as route opens to broader Anktiva label - pharmaphorum
Regulatory Clarity Fuels Surge for ImmunityBio Shares - AD HOC NEWS
Why ImmunityBio Stock Is Skyrocketing Again Today - AOL.com
ImmunityBio Approval And Trial Updates Spark Valuation Debate For Investors - simplywall.st
ImmunityBio Stock (IBRX) Keeps Flying as FDA Update Fuels Momentum - TipRanks
ImmunityBio Stock Jumps 26% as FDA Sets ANKTIVA Resubmission Path - filmogaz.com
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next - TechStock²
Stock Market Today, Jan. 20: ImmunityBio Soars Again After FDA Outlines Resubmission Path for ANKTIVA in Bladder Cancer - The Motley Fool
ImmunityBio Shares Surge on Regulatory Pathway Clarity - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Shares Gap UpHere's What Happened - MarketBeat
Why Is ImmunityBio Stock Trading Higher TodayImmunityBio (NASDAQ:IBRX) - Benzinga
This FDA Signal Is Powering IBRX Stock's Pre-Market Jump - Stocktwits
ImmunityBio Extends Rally After FDA Talks - Yahoo Finance
Best Biotech Stocks To Add to Your WatchlistJanuary 20th - MarketBeat
ImmunityBio shares jump on Anktiva resubmission hopes - The Pharma Letter
Immunitybio Inc Azioni (IBRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.38%
1.95%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):